ModifiedUnitedHealthcarePolicy CS054PA.V

Airway Clearance Devices (for Pennsylvania Only)

Governs medical necessity and coverage of airway clearance devices including HFCWO systems and IPV for UnitedHealthcare members in Pennsylvania; affects providers requesting rental or purchase of these devices.

Policy Summary

PayerUnitedHealthcare

PolicyAirway Clearance Devices (for Pennsylvania Only)

Policy CodePolicy CS054PA.V

Change TypeClinical criteria reviseddocumentation clarifications added

Effective DateApr 1, 2026

Next Review Date

Key ActionRequire an initial 2-month rental trial of an HFCWO system and provide supporting medical records to confirm tolerance and efficacy before approving ongoing coverage.

SourceLink

POLICY UPDATE CHANGES

Updated language pertaining to medical necessity clinical coverage criteria for a high-frequency chest wall oscillation (HFCWO) system.

Added language clarifying that medical records documentation may be required to assess whether the member meets clinical criteria and listing types of documentation expected.

Updated Description of Services, Clinical Evidence, and References sections to reflect most current information.

2-monthrental trial required for HFCWO

PA-onlypolicy applies to state

6 codes

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

procedure/HCPCS codes listed

low–very lowevidence certainty

multiple RCTs & SRsstudies summarized

Coverage Criteria and Evidence Summary

HFCWO coverage and exclusions

Covered when ALL of the following are met:

HFCWO initial coverage

Permitted diagnoses: Neuromuscular diseases OR Bronchiectasis OR Cystic Fibrosis
InterQual criteria referenced for additional clinical coverage criteria.

Devices considered not medically necessary: Use of HFCWO for indications other than neuromuscular disease, bronchiectasis, and cystic fibrosis; combination continuous PEP/continuous high-frequency oscillation/nebulized medication (OLE) devices; intrapulmonary percussive ventilation (IPV) devices for home use

Classified as unproven or not medically necessary due to insufficient evidence.

Unproven / Not Medically Necessary — summary

Summary coverage determinations from this section of the document:

OLE devices not medically necessary: Combination continuous PEP, continuous high-frequency oscillation, and nebulized medication therapy devices for oscillation and lung expansion (OLE) are considered unproven and not medically necessary due to insufficient quality evidence or consistency of findings.

Informational Evidence Summaries

Evidence-based considerations relevant to medical necessity decisions (informational — no explicit covered criteria provided in this fragment):

Equivalence / insufficient evidence: Systematic reviews and meta-analyses report low- to very low-certainty evidence that HFCWO and other oscillatory devices are generally comparable to other airway clearance techniques for many outcomes; individual trials show mixed short-term benefits but insufficient long-term data.

May support coverage in specific clinical contexts where documented benefit exists, but document does not provide explicit covered criteria.

Observational benefit signals: Registry and cohort studies report reductions in hospitalizations, antibiotic use, and improved patient-reported respiratory health after initiation of HFCWO in bronchiectasis and neuromuscular disease, but these observational findings are nonrandomized and may reflect confounding.

Observational improvements alone are insufficient to establish broad coverage policies without RCT confirmation.

Oscillatory devices (general) — evidence summary

Summary of systematic review findings — not a binary coverage rule but evidentiary basis for policy decisions.

Evidence summary: Systematic reviews found low-to-very-low quality evidence and no clear overall superiority of oscillating devices (oral or chest wall) compared with other airway clearance techniques; device-to-device superiority was not demonstrated.

Morrison & Milroy: 39 studies, 1,114 individuals; limited meta-analysis due to heterogeneity and poor reporting.

OLE combination therapy — surgical patients

Findings from a multicenter prospective study assessing OLE in high-risk postoperative patients.

Huynh et al. findings: In a nonrandomized multicenter prospective study (n=419), OLE treatment was associated with decreased postoperative pulmonary complications (22.9% to 15.8%), reduced ventilator time, and shorter hospital length of stay after adjustment for confounders.

Study was nonrandomized; stage II received OLE plus standard care versus an earlier cohort.

Intrapulmonary percussive ventilation (IPV)

Evidence for IPV across ICU and chronic airway disease settings is mixed and generally weak.

Clinical trials and reviews: Some RCTs and systematic reviews report shorter ICU length of stay, modest oxygenation improvements, and reduced respiratory rate with IPV in critically ill cohorts, and short-term symptomatic or physiologic improvements in COPD; however, evidence is weak, heterogeneous, and limited by small sample sizes and study quality.

Hassan et al. RCT (2024) n=106; Hassan systematic review found 7 ICU studies (630 individuals); Nicolini RCT (2018) n=63 showed some IPV benefit in COPD but was small and short-term.

Guideline-based considerations and neuromuscular disease

Society statements inform device selection and patient assessment.

Neuromuscular disease guidance: ATS and BTS recommend assessment of cough effectiveness (peak cough flow) and use of assisted cough technologies when PCF < 270 L/min or maximal expiratory pressures < 60 cm H2O; ATS supports mechanical insufflation–exsufflation (MI-E) and recommends early training and intervention in Duchenne muscular dystrophy. NICE recommends individualized ACT plans for cystic fibrosis and advises not offering HFCWO except in exceptional circumstances.

Guideline recommendations to guide clinical decision-making rather than direct coverage rules.

Coverage Rationale (summary)

Policy updated: coverage is based on clinical medical necessity criteria (see full policy and InterQual criteria).

Coverage requires clinical criteria and documentation: Coverage for HFCWO systems requires meeting UnitedHealthcare medical necessity clinical coverage criteria and adequate supporting medical records per federal, state, or contractual requirements.

Full nested criteria (diagnoses, prior trials, functional thresholds) and InterQual guidance are contained in referenced sections; medical records must be legible and made available upon request.

An initial 2-month rental trial of a high-frequency chest wall oscillation (HFCWO) system is required and considered medically necessary when used to manage neuromuscular diseases, bronchiectasis, or cystic fibrosis and when the specific clinical criteria are met. The rental trial must confirm individual tolerance and efficacy with the device before ongoing medical necessity is determined. HFCWO use outside these indications is classified as unproven due to insufficient evidence of efficacy.

Combination devices that deliver continuous positive expiratory pressure together with continuous high-frequency oscillation and nebulized medication therapy for oscillation and lung expansion (OLE devices) are considered unproven and not medically necessary due to insufficient quality of evidence and inconsistent findings across studies. Systematic reviews report low- to very-low certainty and do not demonstrate clear superiority of oscillatory combination therapies over other airway clearance techniques.

The National Institute for Health and Care Excellence (NICE) advises not offering HFCWO as an airway clearance technique for people with cystic fibrosis except in exceptional clinical circumstances; such decisions should be made by the specialist cystic fibrosis team and handled through NHS England individual funding processes. NICE notes evidence that HFCWO is not as effective as other standard ACTs.

FDA clearance or approval of a device is provided for informational purposes only and does not by itself establish coverage. Benefit determination and coverage remain governed by applicable federal, state, or contractual requirements; in the event of conflict, those requirements take precedence. UnitedHealthcare may also use tools such as InterQual® criteria to assist in administering benefits.

HFCWO and other oscillatory therapies are considered unproven for indications outside neuromuscular disease, bronchiectasis, and cystic fibrosis. Systematic reviews and the policy conclusion indicate insufficient high-quality evidence to support medical necessity for other conditions.

Due to limited, heterogeneous, and generally low- to very-low–quality evidence, OLE combination devices are classified as not medically necessary. Studies show inconsistent effects on outcomes and do not establish benefit sufficient to support routine coverage of these devices.

Routine long-term home use of oscillatory devices or intrapulmonary percussive ventilation (IPV) is not supported without documented clinical justification. Systematic reviews and trials report weak or inconsistent benefits, and ongoing coverage generally requires objective documentation of benefit from an initial trial and supporting clinical data.

Reiterating policy guidance, FDA approval alone does not establish medical necessity or coverage. Coverage decisions are subject to the federal, state, or contractual terms that govern the member’s benefit plan and may differ from the conclusions in this policy.

Applicable Billing and Diagnosis Codes

Applicable HCPCS/CPT/RevenueHCPCS

A7021	Supplies and accessories for lung expansion airway clearance, continuous high frequency oscillation, and nebulization device (e.g., handset, nebulizer kit, biofilter).
A7025	High frequency chest wall oscillation system vest, replacement for use with patient- owned equipment, each.
A7026	High frequency chest wall oscillation system hose, replacement for use with patient- owned equipment, each.
E0469	Lung expansion airway clearance, continuous high frequency oscillation, and nebulization device.
E0481	Intrapulmonary percussive ventilation system and related accessories.
E0483	High frequency chest wall oscillation system, with full anterior and/or posterior thoracic region receiving simultaneous external oscillation, includes all accessories and supplies, each.

Applicable ICD-10 Diagnosis Codes (selected)ICD-10

A80.0	Acute paralytic poliomyelitis, vaccine-associated.
E84.0	Cystic fibrosis with pulmonary manifestations.
J47.9	Bronchiectasis, uncomplicated.
G12.21	Amyotrophic lateral sclerosis.
G12.0	Infantile spinal muscular atrophy, type I [Werdnig-Hoffman].
G71.11	Myotonic muscular dystrophy.
Z99.11	Dependence on respirator [ventilator] status.

Device identifiers / FDA codesmixed

product code BYI

FDA product code referenced for HFCWC devices

Device/Product Codes (informational)mixed

No codes listed

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior authorization likely required for OLE devices

Prior authorization may be required for combination OLE devices (continuous PEP + continuous high-frequency oscillation + nebulized medication) because these devices are considered unproven and not medically necessary due to insufficient quality and consistency of evidence. Requests for these devices are likely to be denied without strong supporting clinical justification.

OLE devices (combination continuous PEP + continuous HFO + nebulized therapy) — considered unproven/not medically necessary
Denials likely if submitted without documentation of exceptional clinical rationale

Prior Authorization

Prior authorization for HFCWC/HFCWO

Prior authorization is generally required for high-frequency chest wall compression/oscillation (HFCWC/HFCWO) devices when used for management of neuromuscular disease, bronchiectasis, or cystic fibrosis and when external chest manipulation is the physicians treatment of choice. An initial 2-month rental trial is required to establish tolerance and effectiveness before ongoing rental or purchase will be considered medically necessary.

Background and Context

Airway clearance may be inadequate in conditions such as cystic fibrosis, bronchiectasis, and neuromuscular disorders, leading to secretion retention, infection risk, and impaired gas exchange. Device-based therapies aim to augment mucus mobilization—HFCWO systems apply external chest compression via an inflatable vest, while IPV delivers internal percussive gas bursts. Evidence supports a supervised 2-month rental trial of HFCWO for specified diagnoses to assess tolerability and clinical response; however, many oscillatory therapies lack high-certainty evidence and should be considered only when clinically justified and documented.

Definitions

Bronchiectasis definition

DefinitionBronchiectasis is a chronic respiratory disease characterized by dilation (ectasia) of the airways or bronchi with recurrent, chronic, or refractory infections; clinically significant bronchiectasis has at least two of: cough most days, sputum production most days, or history of exacerbations, and is confirmed radiographically by CT.

Primary manifestationsRecurrent, chronic, or refractory respiratory infections and persistent cough with sputum production.

Diagnostic confirmationRadiographic confirmation and classification by high-resolution, spiral, or standard computed tomography scan.

OLE devices — combination device definition

DefinitionOLE devices are combination systems that provide continuous positive expiratory pressure (PEP), continuous high-frequency oscillation, and nebulized medication therapy for oscillation and lung expansion.

Policy Summary

PayerUnitedHealthcare

PolicyAirway Clearance Devices (for Pennsylvania Only)

Policy CodePolicy CS054PA.V

Change TypeClinical criteria reviseddocumentation clarifications added

Effective DateApr 1, 2026

Next Review Date

Key ActionRequire an initial 2-month rental trial of an HFCWO system and provide supporting medical records to confirm tolerance and efficacy before approving ongoing coverage.

SourceLink

On This Page

Indications with prior auth likely: neuromuscular disease, bronchiectasis, cystic fibrosis
Initial 2-month rental trial required to confirm tolerance and efficacy before ongoing coverage

Prior Authorization

Prior authorization guidance

Use this policy in conjunction with applicable federal, state, and contractual benefit requirements. UnitedHealthcare may use InterQual criteria to adjudicate medical necessity; reviewers may apply InterQual Client Defined Airway or Secretion Clearance Devices criteria when determining coverage.

Coverage subject to federal/state/contract requirements
InterQual Client Defined, CP: Durable Medical Equipment, Airway or Secretion Clearance Devices (Custom) - UHG may be used

Denial Risk

Denial triggers

Requests that fall outside the specified medically necessary indications or lack required supporting documentation may be denied as unproven and not medically necessary.

Requests for HFCWO or OLE devices for indications not specified as medically necessary — denial risk

Denial Risk

Insufficient evidence may lead to noncoverage

Insufficient or low-quality evidence for certain devices (for example, OLE devices, intrapulmonary percussive ventilation for home use) may result in noncoverage. Evidence limitations cited include low or very low certainty, inconsistent findings, and lack of long-term randomized controlled data.

OLE devices and home IPV — considered unproven due to low/very-low quality evidence
Lack of clear superiority or consistent benefit in RCTs and systematic reviews

Documentation Required

Documentation-dependent coverage

Coverage determination is documentation-dependent. Benefit coverage is governed by federal, state, or contractual requirements; lack of required documentation or failure to meet those requirements may result in denial.

Coverage determined by federal/state/contract; policy language does not override benefit terms
Incomplete documentation may lead to coverage denial

Documentation Required

Medical records required

The patients medical record must contain documentation that fully supports medical necessity. Documentation should include relevant medical history, physical examination findings, and results of pertinent diagnostic tests or procedures. Records must be legible, maintained in the medical record, and made available upon request.

Include relevant history, physical exam, and diagnostic test results
Records must be legible and available upon request

Documentation Required

Documentation limitations noted

Administrative claims-based studies and some published reports lack device-use detail and other methodological limitations; reviewers note these documentation limitations when assessing the strength of evidence for coverage decisions.

Administrative claims studies may not capture how HFCWO was used
Limitations may affect interpretation of outcomes and coverage determinations

Documentation Required

Required clinical documentation

For postoperative or neuromuscular patients and others under consideration for airway clearance devices, required clinical documentation should include assessment of risk status, objective measures of effectiveness, and baseline and follow-up outcome data (for example, cough peak flow, maximal expiratory pressures, frequency of exacerbations, health care utilization). For DMD and similar neuromuscular disorders, document use of or need for assisted cough when cough is ineffective.

Document risk status and objective outcomes for postoperative patients
Document cough peak flow (PCF) or maximal expiratory pressures and use of assisted cough measures for neuromuscular disease

Prior Authorization

Trial before ongoing coverage

An initial 2-month rental trial must be documented to confirm individual tolerance and clinical benefit before ongoing rental or purchase is authorized. Documentation of adherence, symptom improvement, reduced exacerbations or healthcare utilization, or other objective benefit should be included to support continued coverage.

Document 2-month rental trial start and end dates and objective measures of benefit
Continuation of coverage requires demonstrated tolerance and efficacy

Coverage stanceConsidered unproven and not medically necessary due to insufficient quality evidence or consistency of findings.

Typical intended useDesigned to combine oscillation and lung expansion therapies, often evaluated in postoperative or high-risk patients.

PEP — positive expiratory pressure device definition

DefinitionPositive expiratory pressure (PEP) devices are airway clearance tools that apply expiratory pressure (often via mask or mouthpiece) to aid mucus clearance.

Clinical evidence notePEP has been compared with other physiotherapy techniques in multiple RCTs with mixed short-term effects on FEV1 and some long-term reduction in exacerbations when used with a mask for ≥1 year.

Common deliveryDelivered using a mask (most studies) or mouthpiece with nose clips in some trials.

High-frequency chest wall compression (HFCWC) — external chest manipulation therapy

DefinitionHigh-frequency chest wall compression (HFCWC) is a device-based external chest manipulation therapy designed to promote airway clearance and improve bronchial drainage when external chest manipulation is the physician's treatment of choice.

MechanismUses external chest compression (e.g., inflatable vest with air-pulse generator) to enhance mucus transport and bronchial drainage.

Indication contextIndicated when external chest manipulation is the physician's treatment of choice to enhance mucus transport.

Intrapulmonary percussive ventilation (IPV) — definition and intended effects

DefinitionIntrapulmonary percussive ventilation (IPV) is an internal percussive ventilation therapy that delivers rapid mini-bursts of gas to mobilize secretions and potentially improve gas exchange and respiratory parameters.

Intended effectsAims to aid airway clearance, improve oxygenation and respiratory rate, and in some ICU trials reduce ICU length of stay.

Evidence summaryEvidence is mixed and generally weak; some RCTs and systematic reviews report modest short-term physiologic or clinical improvements but limited long-term data and heterogeneity across studies.

OLE combination therapy — oscillation and lung expansion definition

DefinitionOLE combination therapy refers to combined continuous high-frequency oscillation plus continuous positive expiratory pressure (with nebulized medication) intended to provide oscillation and lung expansion together.

Intended clinical goalDesigned to reduce postoperative pulmonary complications and resource use in high-risk surgical patients when added to standard respiratory care.

Evidence and stanceSome nonrandomized prospective data suggest reduced postoperative pulmonary complications, ventilator time, and hospital length of stay, but overall evidence quality is insufficient to support routine coverage.

High-frequency chest wall compression devices (HFCWO) — device description and indication

Device descriptionHigh-frequency chest wall oscillation (HFCWO) devices are external systems (e.g., inflatable vest with air-pulse generator) designed to promote airway clearance and improve bronchial drainage.

IndicationIndicated when external chest manipulation is the physician's treatment of choice to enhance mucus transport.

Regulatory noteFDA product code BYI is referenced for these devices; FDA approval alone is informational and not a basis for coverage determinations.